Amgen (NASDAQ:AMGN) and AstraZeneca Plc, announced an agreement to jointly develop and commercialize five monoclonal antibodies from Amgen's clinical inflammation portfolio (AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab (AMG 827)).

Novartis and the Broad Institute have developed a cancer cell line encyclopedia that catalogues the genetic and molecular profiles of almost 1,000 human cancer cell lines used in drug research and development. Results of the collaboration, published in the journal Nature, may allow scientists around the world to use this information to improve cancer clinical trial design and further cancer research.

Bayer HealthCare Company Ltd and Tsinghua University in Beijing, China, are expanding their joint research partnership relating to the Bayer-Tsinghua Joint Research Center for Innovative Drug Discovery (BTC). This week, both partners signed a new strategic agreement to collaborate in the area of biomedical sciences over the next 3 years.

Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) presented data from two Phase 2 trials with SAR236553/REGN727, an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9)

The US District Court for the District of Columbia issued an opinion and order in AstraZeneca's lawsuit against the US Food and Drug Administration (FDA) regarding final marketing approval of generic quetiapine. The Court denied the company's request for a preliminary injunction and dismissed the lawsuit without prejudice.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced results from the Phase III HannaH study in women with HER2-positive early breast cancer (eBC) showing for the first time that a new way of giving Herceptin (trastuzumab) by subcutaneous (SC) injection leads to comparable efficacy (based on pathological complete response (pCR);

AstraZeneca announced that the High Court in the UK has rendered its opinion on the formulation patent protecting SEROQUEL XR® (quetiapine fumarate) prolonged-release tablets currently pending in the UK court. The court found the formulation patent protecting SEROQUEL XR (marketed as SEROQUEL XL in the UK) to be invalid.